RDC (Radionuclide Drug Conjugate), a novel trend in bioconjugation drug development, has multiple uses in clinical diagnostic and treatment. Four components are needed in RDC, including radionuclide, chelator, linker, and delivery part. Three kinds of delivery parts, including antibodies, small molecules, and peptides are utilized in RDC.
Focusing on RDC development for decades with our professional RDC development platform, Alfa Cytology is capable to provide premium quality and cost-effective services throughout the whole process of RDC development.
Fig.1 Illustration of RDC targeting the cancer cell.
RDC is a bifunctional radiopharmaceutical with two essential parts, including a radionuclide and a targeting molecule. The radionuclide is utilized as the effective part to conduct cancer cell damaging and diagnostic imaging at the cell level, while the targeting molecule is the delivery vehicle to drive the RDC to the diseased tissue. Based on the different types of targeting molecules, the RDC can be divided into three categories, containing antibody-based RDC, small molecule-based RDC, and peptide-based RDC.
Three types of radioactive particles are used in RDC, covering alpha, beta, and gamma particles. According to the different kinds of radioactive beams emitted by the particles, the RDC has two different utilizes in clinical applications. After injection into the patient's body, the RDC drug is carried through the circulatory system by targeted molecules, working as a vector, to the site of the disease, where it works in the cancerous tissue.
Diagnostic Imaging
The gamma-emitting radionuclides with the most penetrating radioactive beams are widely used to conduct diagnostic imaging at the cell level.
Cancer Treatment
The alpha- and beta- emitting radioactive particles with less penetrating radioactive beams play a significant role in damaging cancer cells accurately.
As a novel radiopharmaceutical, RDC is approved to apply in various utilizes of many types of cancers now.
Through decades of expertise in the designing and synthesizing of radioactive drug conjugates, Alfa Cytology can provide end-to-end RDC development services. Equipped with a rigorous quality management system, a premier scientific team, and modern facilities, we ensure that high-quality RDC conjugation services are available to facilitate the acceleration of your pipeline.
|
Experienced Focused on RDC research for decades, Alfa Cytology is capable to provide high-quality and cost-effective RDC development service for your special RDC project with the best scheme design and conjugation service to meet your demand |
|
Flexible Alfa Cytology can provide all kinds of services through the whole RDC development process, including custom development and conjugation services according to your interests and lateral RDC analysis services |
|
Integrated With an experienced research team and top-notched equipment, Alfa Cytology enable seamless scaling of RDC products from drug production to preclinical development. Collaborate across functional teams to promote your RDC development. |
Alfa Cytology can provide one-step service and customized service through the whole RDC development process. Please contact us for more information.
For research use only. Not intended for any clinical use.
Alfa Cytology, a provider of RDC preclinical services, specializes in RDC design, conjugation, and analysis. Supported by a rich library of radionuclides, chelators, and linkers, we excel in targeting molecule design. We offer customized RDC services tailored to diverse requirements-your demand is our mission.
Copyright © 2025 Alfa Cytology. All rights reserved.
